The most effective drug for Alzheimer’s will be blocked for use on the NHS on Wednesday. Regulators are expected to declare ...

A clinical trial is testing whether an existing drug could benefit patients with Alzheimer’s disease, in hopes of making ...

Alzheimer’s disease is the leading cause of dementia in the UK. It’s a complex, challenging, and devastating condition that causes a gradual decline in a person’s cognition, including memory and ...

In late 2022, the results of a groundbreaking stage three trial for a ‘miracle’ new Alzheimer’s drug lecanemab were hailed as ...

On Oct. 5, Rancho Santa Fe’s charity group The Frostys served as the entertainment along the route of the Alzheimer’s ...

The Permian Basin's Walk to End Alzheimer's is coming up Oct. 26. The event opens at 9 a.m. at Scharbauer Sports Complex-Coterra Pavilion, 5514 Champions Drive, in Midland. The opening ceremony is at ...

Leqembi, first FDA-approved Alzheimer's drug, faces EMA rejection, but shares could potentially surge soon. See why I rate ...

Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s ...

Listen to episode nine, “Executing Clinical Research in Dementia with Lewy Bodies (DLB)” on the Conversations tab of the Cognition website. This conversation is presented in 3 Chapters: 1) Comparing ...

Health Alzheimer's Disease study plans to study 2,000 volunteers' brain scans and blood work to identify biomarkers of dementia-causing diseases sooner.

A new Macquarie University study suggests that instead of relying on the 'bible' of mental health diagnosis, we need a ...

A new study distinguishes between two distinct phases of Alzheimer's disease: an early, 'stealth' one without symptoms, and a ...